Axicabtagene Ciloleucel – Uses, Dosage, Side Effects, Interaction

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Axicabtagene Ciloleucel - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Axicabtagene ciloleucel is a CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma. Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Axicabtagene ciloleucel is a CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma. Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in the immune response to cancer.[rx] Once T-cells are collected from the patient, they are genetically engineered...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Axicabtagene ciloleucel is a CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma.

Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient’s own T cells, which play a central role in the immune response to cancer.[rx] Once T-cells are collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and kill cancer cells, and are infused back into the patient.2 Each dose of axicabtagene ciloleucel represent the patient’s genetically modified T-cells.[rx] The development of resulted from early preclinical studies conducted by a group of researchers at the National Cancer Institute (NCI), who demonstrated that T cells expressing an anti-CD19 CAR can produce cytokines that efficiently kill leukemic cells in vitro.[rx]

Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults.[rx] Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018.[rx]

Mechanism of action

The CD 19 antigen is an integral membrane glycoprotein normally expressed in B cells during differentiation; however, it is often aberrantly expressed on B cells that have undergone a neoplastic transformation. Distinctive expression of CD19 in lymphomas and leukemias makes this glycoprotein a good immunotherapeutic target.[rx]

Axicabtagene ciloleucel is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. It consists of genetically modified T cells of the patient receiving the immunotherapy. The manufacturing of axicabtagene ciloleucel begins with the collection of peripheral blood mononuclear cells from the patient, followed by the harvesting and genetic modification of T cells ex vivo. Retroviral transduction is used to express a CAR on T cells, creating anti-CD19 CAR T cells that are then expanded. Axicabtagene ciloleucel, a suspension of anti-CD19 CAR T cells, is infused back into the patient during treatment.[rx] Axicabtagene ciloleucel is made up of two components: a single-chain variable fragment targets the CD19 proteins, and there are intracellular domains – CD28 and CD3-zeta co-stimulatory domains – that signal T-cell activation.[rx,rx] Once administered into the patient’s bloodstream, axicabtagene ciloleucel recognizes the CD19-expressing target cells and the intracellular domains of the drug activate the downstream signaling cascades that lead to T-cell activation, proliferation, acquisition of effector functions, and secretion of inflammatory cytokines and chemokines that kill cancer cells.[rx] Axicabtagene ciloleucel binds to CD19-expressing cancer cells and normal B cells.[rx]

Indications

  • In the US, axicabtagene ciloleucel is indicated for the treatment of adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.[rx]
  • In the US and Europe, it is used to treat adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.[rx,rx]
  • Axicabtagene ciloleucel is also used to treat adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy in the US,[rx], or three or more lines of systemic therapy in Europe.[rx]
  • Refractory Diffuse Large B Cell Lymphoma (DLBCL)
  • Refractory Follicular Lymphoma
  • Refractory Large B-cell Lymphoma
  • Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
  • Relapsed Follicular Lymphoma
  • Refractory High-Grade B-cell Lymphoma (HGBCL)
  • Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
  • Relapsed High-Grade B-cell Lymphoma (HGBCL)
  • Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
  • B Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma

Use in Cancer

Axicabtagene ciloleucel is approved to treat adults with:

  • B-cell non-Hodgkin lymphoma (NHL), including the following types:
    • Diffuse large B-cell lymphoma (DLBCL).
    • DLBCL in patients who had follicular lymphoma.
    • Follicular lymphoma.¹
    • Primary mediastinal large B-cell lymphoma.
    • High-grade B-cell lymphoma.

      It is used in adults whose cancer relapsed (came back) or did not get better after at least two other systemic therapies.

  • DLBCL that did not respond to first-line chemoimmunotherapy or that relapsed within 12 months of first-line chemoimmunotherapy.

Axicabtagene ciloleucel is only available as part of a special program called Yescarta REMS (Risk Evaluation and Mitigation Strategies).

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that axicabtagene ciloleucel provides a clinical benefit in these patients.

Axicabtagene ciloleucel is also being studied in the treatment of other types of cancer.

Contraindications

The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:

  • a bad infection
  • a type of blood disorder with a decrease in all types of blood cells called pancytopenia
  • leukoencephalopathy is a disease of the white matter of the brain
  • pregnancy
  • resolved hepatitis B
  • reactivation of hepatitis B infection

Dosage

Lymphoma

  • 2 x 10(6) chimeric antigen receptor (CAR)-positive viable T cells IV per kg body weight via IV infusion; infuse within 30 minutes
  • Maximum Dose: 2 x 10(8) CAR-positive viable T cells

Dose Adjustments

CYTOKINE RELEASE SYNDROME (CRS):

  • Identify CRS based on clinical presentation.
  • Evaluate for and treat other causes of fever, hypoxia, and hypotension.
  • If CRS is suspected, manage according to CRS grading.
  • Patients who experience Grade 2 or higher CRS (e.g., hypotension, not responsive to fluids, or hypoxia requiring supplemental oxygenation) should be monitored with continuous cardiac telemetry and pulse oximetry.
  • For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function.
  • For severe or life-threatening CRS, consider intensive care supportive therapy.

CRS GRADING

GRADE 1 (symptoms require symptomatic treatment only [e.g., fever, nausea, fatigue, pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache, myalgia, malaise]): No adjustment recommended.
GRADE 2 (symptoms require and respond to moderate intervention; oxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity:

  • Tocilizumab: Administer 8 mg/kg IV over 1 hour (not to exceed 800 mg) every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen; limit to a maximum of 3 doses in 24 hours; maximum total of 4 doses.
  • Corticosteroids: Manage per Grade 3 if no improvement within 24 hours after starting tocilizumab.

GRADE 3 (symptoms require and respond to aggressive intervention; oxygen requirement greater than or equal to 40% FiO2 or hypotension requiring high-dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis:

  • Tocilizumab: Administer 8 mg/kg IV over 1 hour (not to exceed 800 mg) every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen; limit to a maximum of 3 doses in 24 hours; maximum total of 4 doses.
  • Corticosteroids: Administer methylprednisolone 1 mg/kg IV 2 times a day or equivalent dexamethasone (e.g., 10 mg IV every 6 hours); continue corticosteroids use until the event is Grade 1 or less, then taper over 3 days.

GRADE 4 (life-threatening symptoms; requirements for ventilator support, continuous venovenous hemodialysis (CVVHD) or Grade 4 organ toxicity (excluding transaminitis):

  • Tocilizumab: Administer 8 mg/kg IV over 1 hour (not to exceed 800 mg) every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen; limit to a maximum of 3 doses in 24 hours; maximum total of 4 doses.
  • Corticosteroids: Administer methylprednisolone 1000 mg IV daily for 3 days; if improves, then manage as detailed for Grade 3.

NEUROLOGIC TOXICITY
Grade 2 or Higher:

  • Monitor patients for neurologic toxicities (Table 2).
  • Rule out other causes of neurologic symptoms.
  • Patients who experience Grade 2 or higher neurologic toxicities should be monitored with continuous cardiac telemetry and pulse oximetry.
  • Provide intensive care supportive therapy for severe or life-threatening neurologic toxicities. Consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis for any Grade 2 or higher neurologic toxicities.

NEUROLOGIC TOXICITY GRADING AND MANAGEMENT GUIDANCE:
GRADE 2:

  • Concurrent CRS: Administer tocilizumab per Table 1 for management of Grade 2 CRS; if no improvement within 24 hours after starting tocilizumab, administer dexamethasone 10 mg IV every 6 hours if not already taking other corticosteroids; continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days; consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.
  • No concurrent CRS: Administer dexamethasone 10 mg IV every 6 hours; continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days; consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.

GRADE 3:

  • Concurrent CRS: Administer tocilizumab per Table 1 for management of Grade 2 CRS; in addition, administer dexamethasone 10 mg IV with the first dose of tocilizumab and repeat every 6 hours; continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days; consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.
  • No concurrent CRS: Administer dexamethasone 10 mg IV every 6 hours; continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days; consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.

GRADE 4:

  • Concurrent CRS: Administer tocilizumab per Table 1 for management of Grade 2 CRS; administer methylprednisolone 1000 mg IV per day with first dose of tocilizumab and continue methylprednisolone 1000 mg IV per day for 2 more days; if improves, then manage as above; consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.
  • No concurrent CRS: Administer methylprednisolone 1000 mg IV per day for 3 days; if improves, then manage as above; consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.

Side Effects

The Most Common

  • constipation
  • stomach pain
  • pain: Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।" data-rx-term="back pain" data-rx-definition="Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।">back pain
  • joint or muscle pain
  • dry mouth
  • loss of appetite
  • weight loss
  • blood in urine
  • bleeding more easily than normal
  • fever, sore throat, chills, or other signs of infection
  • decreased urination frequency or amount
  • pale skin
  • fatigue
  • swelling of the eyes, face, lips, tongue, throat, arms, hands, feet, ankles, or lower legs
  • difficulty swallowing
  • rash
  • hives
  • itching

More Common

  • headaches, dizziness;
  • tremors, anxiety, trouble sleeping;
  • unusual thoughts or behavior;
  • trouble speaking or understanding what is said to you; or
  • low blood cell counts–fever, chills, tiredness, flu-like symptoms, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands, and feet, feeling light-headed or short of breath.
  • nausea, diarrhea;
  • low blood cells;
  • confusion; or
  • fast heartbeats.

Rare

  • Cardiovascular: Cardiac arrhythmia (23%), edema (19%), hypertension (15%), hypotension (57%), tachycardia (57%)
  • Endocrine & metabolic: Dehydration (11%), hyponatremia (grades 3/4: 19%), hypophosphatemia (grades 3/4: 50%), increased uric acid (grades 3/4: 13%), weight loss (16%)
  • Gastrointestinal: Abdominal pain (14%), constipation (23%), decreased appetite (44%), diarrhea (38%), nausea (34%), vomiting (26%), xerostomia (11%)
  • Hematologic & oncologic: Anemia (grades 3/4: 66%), febrile neutropenia (34% to 36%; grade ≥3: 31%), hypogammaglobulinemia (15%), leukopenia (grades 3/4: 96%), lymphocytopenia (grades 3/4: 100%), neutropenia (grades 3/4: 93%), thrombocytopenia (grades 3/4: 58%)
  • Hepatic: Increased direct serum bilirubin (grades 3/4: 13%)
  • Hypersensitivity: Cytokine release syndrome (94%)
  • Infection: Bacterial infection (13%), infection (26% to 38%, including serious infection; fungal infection: 5%), viral infection (16%)
  • Nervous system: Aphasia (18%), chills (40%), delirium (17%), dizziness (21%), encephalopathy (57%; can last up to 173 days), fatigue (46%), headache (44% to 45%), motor dysfunction (19%)
  • Neuromuscular & skeletal: Back pain (15%), limb pain (17%), myalgia (14%), tremor (31%)
  • Renal: Renal insufficiency (12%)
  • Respiratory: Cough (30%), dyspnea (19%), hypoxia (32%), pleural effusion (13%)
  • Miscellaneous: Fever (86%)

Drug Interaction

Pregnancy and Lactation

US FDA pregnancy category Not Assigned

Pregnancy

The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Breastfeeding

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Reference

 

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Axicabtagene Ciloleucel – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…